Lindsey Trickett - Intellia Therapeutics Vice President - Investor Relations
| NTLA Stock | USD 21.40 0.58 2.64% |
President
Lindsey Trickett is Vice President - Investor Relations of Intellia Therapeutics since 2018.
| Tenure | 6 years |
| Address | 40 Erie Street, Cambridge, MA, United States, 02139 |
| Phone | 857 285 6200 |
| Web | https://www.intelliatx.com |
Intellia Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2283) % which means that it has lost $0.2283 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.421) %, meaning that it created substantial loss on money invested by shareholders. Intellia Therapeutics' management efficiency ratios could be used to measure how well Intellia Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of April 30, 2024, Return On Tangible Assets is expected to decline to -0.39. In addition to that, Return On Capital Employed is expected to decline to -0.46. At present, Intellia Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 317.8 M, whereas Total Assets are forecasted to decline to about 686.6 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Paul Silva | Vertex Pharmaceuticals | 51 | |
| Jim Beitel | Fate Therapeutics | N/A | |
| Michael Partridge | Vertex Pharmaceuticals | N/A | |
| John Gray | Vertex Pharmaceuticals | 53 | |
| Wendy Levin | Fate Therapeutics | N/A | |
| Amit Sachdev | Vertex Pharmaceuticals | 50 | |
| Ian Smith | Vertex Pharmaceuticals | 51 | |
| Michael Parini | Vertex Pharmaceuticals | 43 | |
| YuWaye Chu | Fate Therapeutics | N/A | |
| Charles Wagner | Vertex Pharmaceuticals | 56 | |
| Sarah Cooley | Fate Therapeutics | N/A | |
| Thomas Graney | Vertex Pharmaceuticals | 52 | |
| Jeffrey Chodakewitz | Vertex Pharmaceuticals | 60 | |
| Kala Subramanian | Crispr Therapeutics AG | 49 | |
| Reshma Kewalramani | Vertex Pharmaceuticals | 45 | |
| John Ferraro | Fate Therapeutics | N/A | |
| Megan Menner | Crispr Therapeutics AG | N/A | |
| Andrew JD | Verve Therapeutics | 57 | |
| Charles Milstein | Vertex Pharmaceuticals | 42 | |
| Kimberly White | Vertex Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.42 | ||||
| Return On Asset | -0.23 |
Intellia Therapeutics Leadership Team
Elected by the shareholders, the Intellia Therapeutics' board of directors comprises two types of representatives: Intellia Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Intellia. The board's role is to monitor Intellia Therapeutics' management team and ensure that shareholders' interests are well served. Intellia Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Intellia Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jennifer Doudna, Founder Board | ||
| Jose Rivera, COO, Chief Legal Officer | ||
| Derek Hicks, Executive Officer | ||
| Andrew May, Founder Board | ||
| John Leonard, Executive Vice President - Research and Development | ||
| Laura SeppLorenzino, Executive Vice President Chief Scientific Officer | ||
| John MD, CEO President | ||
| Rachel Haurwitz, CoFounder | ||
| Perry Karsen, Chairman of the Board | ||
| Andrew Schiermeier, Executive Vice President -Corporate Strategy and Development | ||
| Frank Verwiel, Director | ||
| Moncef Slaoui, Director | ||
| Derrick Rossi, Founder Board | ||
| Jesse Goodman, Director | ||
| Caroline Dorsa, Independent Director | ||
| Fred Cohen, Director | ||
| JeanFrancois Formela, Independent Director | ||
| Carl Gordon, Independent Director | ||
| JD Esq, General VP | ||
| Lina Li, Senior Manager, Investor Relations | ||
| Lindsey Trickett, Vice President - Investor Relations | ||
| Nessan Bermingham, President CEO, Founder, Director | ||
| David Morrissey, CTO | ||
| Graeme Bell, CFO, Executive Vice President | ||
| Glenn CPA, CFO VP | ||
| Glenn Goddard, CFO, Executive Vice President | ||
| Sapna Srivastava, Chief Finance and Strategy Officer | ||
| David MD, Executive Officer |
Intellia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Intellia Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.42 | ||||
| Return On Asset | -0.23 | ||||
| Operating Margin | 72.97 % | ||||
| Current Valuation | 1.32 B | ||||
| Shares Outstanding | 96.11 M | ||||
| Shares Owned By Insiders | 1.36 % | ||||
| Shares Owned By Institutions | 87.29 % | ||||
| Number Of Shares Shorted | 14.59 M | ||||
| Price To Earning | (19.91) X | ||||
| Price To Book | 2.22 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Intellia Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Complementary Tools for Intellia Stock analysis
When running Intellia Therapeutics' price analysis, check to measure Intellia Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intellia Therapeutics is operating at the current time. Most of Intellia Therapeutics' value examination focuses on studying past and present price action to predict the probability of Intellia Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intellia Therapeutics' price. Additionally, you may evaluate how the addition of Intellia Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |
Is Intellia Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intellia Therapeutics. If investors know Intellia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intellia Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.42) | Revenue Per Share 0.409 | Quarterly Revenue Growth (0.1) | Return On Assets (0.23) | Return On Equity (0.42) |
The market value of Intellia Therapeutics is measured differently than its book value, which is the value of Intellia that is recorded on the company's balance sheet. Investors also form their own opinion of Intellia Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Intellia Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intellia Therapeutics' market value can be influenced by many factors that don't directly affect Intellia Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intellia Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Intellia Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intellia Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.